Sohang Chatterjee
Co-Founder, CEO and Director

Praesidia Biotherapeutics, Inc. (Private)

“As we look at the last six months of working with Allele in completing our Series A financing, we are delighted we decided to work with them… an extension of management team… fair and forthcoming with partnership terms…. helped prepare and refine our corporate deck, rehearse interactions with investors, and fine tune our corporate strategy and timelines."

Howard Berman, PhD
Co-Founder and CEO

Coya Therapeutics, Inc. (NASDAQ: COYA)

“Coya is funded today because of the expertise and professionalism of the Allele Capital Team… superior knowledge of science and capital markets… understood our value proposition and asked the right questions… cost to access capital is much lower than traditional VCs, and much faster"

Eric I. Richman,
CEO & Director

Gain Therapeutics, Inc. (NASDAQ: GANX)

“Working with Allele dramatically reduced our execution risk… Extensive knowledge in life sciences and capital markets contacts… Entire team contributed… Proprietary investment, institutional and accredited investors, partnership approach."

David Moss,
Co-Founder & CFO

INmune Bio, Inc. (NASDAQ: INMB)

“A first-class organization… Knowledge of how to navigate banking and institutional universe is second to none… Advice was instrumental … They have helped build and finance private and public biotech for many years”​

Dietrich Stephan, PhD
Founder, Chairman and CEO

NeuBase Therapeutics, Inc. (NASDAQ: NBSE)

"World-class professionals … extension of our team, plan and execute capital markets strategy… Deep understanding of the segment, excellent network (investors, board talent, bankers, analysts).… highest integrity - cannot recommend them highly enough.“

Robert Finizio,
Co-Founder & CEO

TherapeuticsMD, Inc. (NASDAQ: TXMD)

"…Advised us on various aspects of our corporate planning and to assist us in raising capital… support us in our company’s growth initiatives through investment, advice and capital markets support… Allele is a value-added advisor and investor"

Shai Novik,
Former CEO

Prolor Biotech, Inc. - Acquired by OPKO Health, Inc. (NASDAQ: OPK) in 2013

“… Shared our vision and believed in our team pre Proof of Concept… Identified risk mitigated scientific strategy of proprietary versions of approved proteins… Invested their own capital and used their network to become a champion of our company“